Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors

Background The ADAPTABLE (Aspirin Dosing: A Patient‐Centric Trial Assessing Benefits and Long‐Term Effectiveness) was a large, pragmatic, randomized controlled trial that found no difference between high‐ versus low‐dose aspirin for secondary prevention of atherosclerotic cardiovascular disease. Whe...

Full description

Bibliographic Details
Main Authors: Saket Girotra, Amanda Stebbins, Lisa Wruck, Guillaume Marquis‐Gravel, Kamal Gupta, Peter Farrehi, Catherine P. Benziger, Mark B. Effron, Jeffrey Whittle, Daniel Muñoz, Sunil Kripalani, R. David Anderson, Sandeep K. Jain, Tamar S. Polonsky, Faraz S. Ahmad, Matthew T. Roe, Russell L. Rothman, Robert A. Harrington, Adrian F. Hernandez, W. Schuyler Jones
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
aspirin
atherosclerotic cardiovascular disease
secondary prevention
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.030385

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.123.030385

Similar Items